Background
The AllTrials campaign (www.alltrials.net) challenges those of us who are involved in 'medical' (which includes nursing) research to ensure that all clinical trials are registered and all results are reported. The campaign is premised on the observation that the findings of around half of the clinical trials that have ever been undertaken have never been published, resulting in clinical decision-making that is based on a biased evidence base. This also means that the risks taken by thousands of patients who consented to take part in an experiment was in vain.
Perhaps the most well publicised example of bad trials reporting is 'study 329'. The trial involved the antidepressant paroxetine (Seroxat). The authors of the trial concluded that the drug was 'generally well tolerated and effective' in depressed adolescents. An independent reanalysis published in the BMJ in 2015 showed, in fact, that the drug was not effective (at least compared with placebo) and underreported an increase in harms (adverse events, specifically suicidal behaviour) in under 18 year olds who participated (Noury et al. 2015) . Simply put, this study shows how bad reporting of clinical trials can put people's lives at risk.
Perhaps, as a consequence, public faith in science (not just the pharmaceutical industry) is declining (EuroScientist 2015) . More optimistically, study 329 might be seen as a watershed moment in medical research. GSK (who manufacture Seroxat) have now signed up to the AllTrials campaign as have 88,381 individuals and 672 organizations (including Wiley that publishes JAN). Signing up to is easy, ensuring open and transparent reporting of clinical trials, it seems to us, is more challenging. For example, Reveiz et al. (2010) reported that only around a third of trials published in top ranked journals were registered. The authors compared a sample of 148 RCTs against CONSORT (http:// www.consort-statement.org) standards and concluded that reporting was suboptimal (Reveiz et al. 2010) . It is surely the key task of editors of scientific journals to ensure that trials are reported to the highest possible standard. We believe there is a need to examine the quality of trials reporting in nursing journals and have undertaken an audit of clinical trials published in JAN over the past five years (July 2011-June 2016).
Methods
We manually reviewed all articles published in the above period. Articles were extracted that (in the title or abstract) reported the findings of a randomized controlled trial (RCT). Two reviewers (AB and DT) evaluated each article against our audit tool. Any discrepancies were resolved by the discussion or by referring to a third member of the team (RG). The audit tool had ten criteria that we considered to be fundamental to reporting findings from a trial: 1. The trial was registered with a recognized registration service (e.g. clinicaltrials.gov); 2. Registration was prospective (if retrospective was a reason given); 3. The full trial protocol was publicly available (If the corresponding author indicated that the full trial protocol was available on request then we emailed them requesting a copy); 4. Conflicts of interest were declared; 5. The reported primary outcome matched what was listed in the protocol/registration documents; 6. All outcomes listed in the protocol were reported; 7. Adverse events were reported; 8. Details of changes (including additional outcomes) to the protocol during the course of the trial were provided; 9. The authors report that their data are available for reanalysis; 10. Results of the trial were positive. In addition, we extracted details of the country where the fieldwork was conducted and the country where the corresponding author was based.
Results
Between July 2011-June 2016, JAN has published 44 RCTs, an average of eight annually. One trial was withdrawn because it was considered to overlap significantly with another article (duplicate publication). Published trials were mostly focused on testing the effectiveness of psychosocial interventions (e.g. relaxation, play therapy, pain management and self-care activities), the majority reported positive findings (n = 33, 77%). Fieldwork for trials was mostly conducted in Europe, North America, Australia and New Zealand (n = 21, 49%) and Asia (n = 19, 42%). Three authors (7%) did not report where the fieldwork was undertaken. Most corresponding authors were also based in Europe, North America, Australia and New Zealand (n = 24, 56%) and Asia (n = 19, 44%).
Just over two thirds of the trials published in JAN were not registered (n = 30, 70%), of the 13 registered trials half were registered retrospectively (i.e. after the trial had started; n = 7, 54%). Four authors (9%) reported they had published a full trial protocol in peer reviewed journals. Where a protocol was not available we wrote to corresponding authors asking them to send us a copy; four of the 30 study authors responded to our mail, one supplied their protocol (non-English language), the remaining three forwarded details of their intervention but not the trial protocol. None of the study authors stated in their article that their trial data were available for reanalysis.
One author had published two articles in JAN with same trial registration number. Most of the authors completed a conflict of interest statement (n = 41, 95%). All of these stated that the study authors had no specific conflicts of interest.
We compared the stated primary outcome from the 13 registered trials with what was reported in the published articles. All trials reported the primary outcome stated in the protocol. The authors of almost a third of the registered trials (n = 4; 31%) reported additional outcomes in the published article that were not listed on the trial registration web page. The authors did not provide a justification for these amendments.
We read all of the articles to identify amendments that had been made to the protocol during the conduct of the trials. Two of the registered trials (15%) provided explicit details of protocol amendments that had been made. We also observed that seven authors had clearly made amendments during the conduct of the trial (e.g. additional outcome measure or amended inclusion criteria); two authors provided justification in the published report.
Adverse events were reported in seven trials (16%). Three study authors stated that no adverse events had been observed during the course of trial.
Discussion
This audit was influenced by the AllTrials campaign. Wiley have done the easy bit and backed the campaign; in this editorial, however, we have shown that there may be serious work to do to get nursing's (reporting) house in order. It is simply not acceptable that so few studies were registered (even retrospectively). It is important that journal editors (and reviewers) are able to check trial protocols to ensure that that the authors did what they said they were going to do and there was no post hoc 'sleight of hand' (e.g. changing of primary outcomes). That we were unable to locate protocols for the majority of published studies is of concern. In our view it is best practice to publish protocols in a peer review journal (in fact JAN explicitly supports this) as a permanent (locked) record of what the research team were intending to do. There can be no excuses, research teams conducting clinical trials must ensure their trials are registered and that a full protocol is available.
In our experience it is almost inevitable that amendments will need to be made to a study protocol over the course of a trial. It may be that authors fear that if reviewers (and presumably editors) see that amendments have been made they may be suspicious of the competence of the research team. In fact, the opposite is true. Good reporting requires absolute transparency and this is what we strongly suggest authors do.
That very few studies reported adverse events (AEs) from their trial is particularly worrying. An adverse event is defined as 'any untoward medical occurrence in a patient (or clinical investigation participant) which does not necessarily have to have a causal relationship with the experimental treatment'. Simply put, if a patient stubbed their toe whilst they were enrolled in a trial this would be considered to be an AE that should be reported. It is virtually impossible for trial authors to have no AEs to report. Reviewers and editors should have picked up on this and required authors to address the deficit. The consequence is that interventions may be promoted without properly understanding harm that might be caused. This, of course, was the problem with study 329, to which we referred earlier.
During this audit we identified two examples of salami slicing (publishing more than one article from a single trial). RG has written about why such practice risks distorting the evidence base (Gray & Baker 2016) . Salami slicing is bad science and editors and reviewers need to be vigilant to the practice.
We suspect that many authors perceive that conflict of interest relates only to involvement with the pharmaceutical industry; this is not the case. It is our view that authors should take a much more inclusive approach to reporting conflicts of interest. We think that subtle conflicts could still have an impact on the reporting of a trial. For example, if a researcher publishes the findings of a trial of a brief psychosocial treatment and has in the past provided training about that intervention then this would constitute a conflict.
Our recommendations
Journals have an important job to do in upholding the scientific method. This audit is a first attempt to reflect on how well nursing is doing at reporting clinical trials. And the answer to the question is that we could be doing much better. JAN is one of the most prestigious journals in nursing, yet most trials were not registered, protocols were not available and few trials reported details of AEs. These are fundamental to good trial reporting and as a profession we must address these issues.
We make the following recommendations:
• Editors, reviewers and authors need to be much more aware of the reporting requirements for clinical trials (CONSORT).
• Trials that have not been registered should not be published. We accept that some trials will be retrospectively registered but suggest that authors provide an explanation as to why.
• Authors should ensure that a full trial protocol is available, ideally published in a peer reviewed journal.
• Authors should provide details about why amendments were made during the conduct of the trial.
• Adverse events must be reported in detail.
• Authors should be as open as possible about any possible competing interests.
